Regencell Bioscience Holdings Limited (NASDAQ:RGC – Get Free Report)’s stock price dropped 4.6% on Thursday . The company traded as low as $6.03 and last traded at $6.02. Approximately 145,481 shares were traded during mid-day trading, a decline of 51% from the average daily volume of 297,599 shares. The stock had previously closed at $6.31.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on RGC shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday, June 24th. Wall Street Zen cut shares of Regencell Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.
Read Our Latest Research Report on RGC
Regencell Bioscience Stock Down 0.2%
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in RGC. Squarepoint Ops LLC acquired a new stake in shares of Regencell Bioscience in the 2nd quarter valued at approximately $1,701,000. BNP Paribas Financial Markets acquired a new stake in Regencell Bioscience in the second quarter valued at $768,000. XTX Topco Ltd bought a new position in shares of Regencell Bioscience in the 3rd quarter valued at about $598,000. Vident Advisory LLC grew its position in shares of Regencell Bioscience by 65.7% in the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after acquiring an additional 11,866 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Regencell Bioscience by 59,113.8% during the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after purchasing an additional 17,143 shares during the last quarter. Institutional investors and hedge funds own 0.13% of the company’s stock.
About Regencell Bioscience
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Featured Stories
- Five stocks we like better than Regencell Bioscience
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
- One of Trump’s Favorite Stocks Just Reported Blowout Earnings
- Amazon’s Robot Push Raises a Bigger Question About Its Next Margin Lever
Receive News & Ratings for Regencell Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regencell Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
